MMJ Recs

JULY 11, 2024

It is often caused by life events such as stress, anxiety, or a significant change in routine. Chronic Insomnia : This type of insomnia occurs at least three nights per week and lasts for three months or longer. Chronic pain conditions, such as arthritis or back pain, can cause discomfort that interferes with sleep.

Sleep 111

Sleep Treatment Research and Development Therapy 111

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

TheAnswerPage

JUNE 10, 2022

Has Nabiximols (a 50:50 THC:CBD oral spray) been evaluated as a therapy for cancer-related pain? Adverse events were dose-related and only the high-dose(11-16 sprays/day) group compared unfavorably with placebo. 2012; 13: 438-449. See the Answer.

Chronic Pain 40

Chronic Pain Therapy Safety Events 40

Cannabis Law Report

JANUARY 12, 2022

The sale will accelerate the development of Gb Sciences’ proprietary Parkinson’s disease and COVID-related Cytokine-Release Syndrome therapies. “This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. LAS VEGAS, Jan. 11, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Veriheal

FEBRUARY 28, 2021

It helps to showcase the 103 countries holding events on this day as well as the thousands of events hosted online worldwide. This year, COVID-19 has dramatically impacted the way events are hosted. Instead of having physical locations, many events have opted to go digital being held online.

Chronic Pain 52

Chronic Pain Events Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 12, 2021

Wesana Health is an emerging life sciences company championing the development and delivery of therapies, including psychedelics, to treat traumatic brain injury (TBI) and related conditions. Her research focuses on using cannabis as a substitute for opioids in chronic pain patients and cannabis’ effect on seniors with chronic pain.

Chronic Pain 52

Chronic Pain Research and Development Medicine Therapy 52

Veriheal

APRIL 18, 2024

CBD (cannabidiol) has been demonstrated to be effective at treating a wide range of mental and physical health disorders, from chronic pain to inflammation, anxiety, insomnia, and much more. In addition, CBD stands out primarily for presenting mild adverse events, the main complaints associated with the use of usual psychotropic drugs.”

Treatment 59

Treatment CBD Chronic Pain Events 59

Cannabis Law Report

MAY 24, 2022

An employer is required to reimburse an employee for medical marijuana when that patient was given a variance for medical marijuana treatment for chronic pain. Dr. Hart filled out an MG-2 variance form requesting authorization to use medical marihuana to treat the claimant’ chronic pain resulting from his work-related injuries.

Chronic Pain 52

Chronic Pain Marijuana Treatment Therapy 52

MMJ Recs

DECEMBER 15, 2023

The use of medical marijuana to treat insomnia has gained attention as a potential alternative or complementary therapy. Insomnia isn’t just a few restless nights; it’s a chronic condition that interferes with an individual’s ability to obtain sufficient and quality sleep, leading to daytime impairment.

Strains 98

Strains Sleep THC Chronic Pain 98

Cannabis Law Report

OCTOBER 19, 2021

a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. No approved TNF inhibitor has ever been dosed orally.

Pharmaceutical 40

Pharmaceutical Therapy Clinical Trials Chronic Pain 40

Cannabis Law Report

JUNE 23, 2021

The study analysed clinical outcomes of the first 312 patients enrolled in the Registry and found that CBMPs were well tolerated with an adverse event incidence of 39 per 100 patients which compares favourably to opioid painkillers such as morphine or codeine. Improved quality of life.

Cannabinoids 45

Cannabinoids Data Chronic Pain Sleep 45

The Joint Blog

AUGUST 30, 2020

Many seniors likely experimented first-hand with cannabis during their youth and are now returning to it as a potential therapy to mitigate many of the health-related symptoms that come with older age, including chronic pain. No significant associations were observed between the frequency of use and adverse events.

Marijuana 52

Marijuana Chronic Pain Events Therapy 52

The Joint Blog

JUNE 28, 2019

It was found that 81% of participants reported “at least moderate improvement in their condition”, and this occurred “without experiencing serious adverse events. ” Below is the study’s full abstract: BACKGROUND: Chronic pain may be treated with medical cannabis. .

Therapy 44

Therapy Treatment Chronic Pain Marijuana 44

Cannabis Law Report

DECEMBER 1, 2021

a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown in these pre-clinical studies to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. About Supera-CBD.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Cannabis Law Report

NOVEMBER 9, 2021

Ketamine Wellness Centers (KWC) is the largest ketamine therapy provider in the United States with 10 clinic locations serving communities across eight states. Since 2011 KWC has been a trusted leader in bringing IV ketamine therapy into mainstream health care. Transaction Summary. About Ketamine Wellness Centers.

Treatment 52

Treatment Therapy Media Access 52

PrestoDoctor

JUNE 23, 2020

After all, there’s a reason why networking events often involve alcohol. Smoking weed is often used as a form of therapy for some. Cannabis is renowned for its efficacy in treating many medical conditions, such as tumors, anxiety, chronic pain , and even certain types of cancer. For Introspection.

Recreational 52

Recreational Chronic Pain Medicine Cannabis 52

Cannabis Law Report

SEPTEMBER 13, 2021

Unlike other therapies, MYMD-1 is designed to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause serious side effects common with traditional therapies that treat inflammation. blockers, all of which require delivery by injection or infusion. About MyMD Pharmaceuticals, Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

SEPTEMBER 20, 2021

We believe VRP324 is the first step toward building our neurological disorder therapy pipeline, expanding the use of our novel delivery platform technologies to multiple categories of neurology,” said Anthony P. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain.

Epilepsy 40

Epilepsy Research and Development Clinical Trials Chronic Pain 40

MMJ Recs

MARCH 2, 2024

A: Qualifying medical conditions in Ohio include cancer, PTSD, chronic pain, epilepsy, and more. These laws encompass various aspects: Patient Eligibility: Patients must have qualifying medical conditions such as cancer or chronic pain to access medical cannabis.

Dispensary 52

Dispensary Patients Marijuana Education 52

Cannabis Law Report

NOVEMBER 16, 2021

Food and Drug Administration clearance of its Investigational New Drug (IND) application for the Phase 2 trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan. a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown in these studies to selectively block TNF-? 646) 421-9523.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

NOVEMBER 23, 2021

a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. No approved TNF inhibitor has ever been dosed orally.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Chronic Pain 40

The Joint Blog

MAY 13, 2020

In the unlikely event that the cannabis is causing severe side effects that require immediate medical attention, dial 911. She is a board certified Adult Geriatric Nurse Practitioner who specializes in cannabis therapy. For more than 20 years, Eloise has worked primarily with cancer, dementia and chronic pain patients.

Blood Pressure 52

Blood Pressure Tincture Cannabinoids Topical 52

MMJ Recs

OCTOBER 2, 2023

Common qualifying conditions include chronic pain, cancer, HIV/AIDS, multiple sclerosis, epilepsy, and glaucoma, among others. With an emphasis on education, The Green Door offers workshops and events to empower patients with knowledge about medical cannabis.

Dispensary 52

Dispensary Patients Environment Conditions 52

Cannabis Law Report

OCTOBER 26, 2021

a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. No approved TNF inhibitor has ever been dosed orally.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Pain and chronic pain were the most common conditions mentioned over the time period and were referred to in 62% of all articles.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

MARCH 19, 2020

5 For example, in March 2019, FDA and the FTC jointly issued warning letters to three marketers of CBD-containing products relating to claims that these products could help to treat Alzheimer’s disease, anxiety, chronic pain, and psoriasis. are adulterated). Anticipate challenges from third parties.

CBD 45

CBD Research and Development Seed-To-Sale Data 45

The Joint Blog

AUGUST 8, 2023

There have been reports of adverse events related to the consumption of these products, particularly among children, who may mistake them for regular snacks due to similar packaging designs. Recently, the Federal Trade Commission (FTC) and the U.S.

Cannabinoids 26

Cannabinoids THC Packaging Safety 26

The Joint Blog

AUGUST 7, 2023

Delta 8 gummies can be easily stashed in a pocket, purse, backpack, or carry-on when traveling, going to shows or events, enjoying outdoor activities, or whenever you want your delta 8 experience handy. Unlike vape pens or cumbersome edibles, gummies are discreet, portable, and require no preparation or equipment before consuming.

Research and Development 26

Research and Development Sleep THC CBD 26

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 105

Treatment Sleep Clinical Trials Data 105

MMJ Recs

JUNE 23, 2024

Their progressive stance not only affords relief to those grappling with chronic pain, debilitating illnesses, and neurological disorders but also underscores a commitment to patient-centric care and holistic wellness. Pennsylvania is among the states that have embraced the medicinal use of cannabis.

Conditions 52

Conditions Marijuana Patients Chronic Pain 52

Healer

JUNE 28, 2019

‘Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.’ Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. 006), mean worst pain (P =.011), ’ Abstract.

Cannabinoids 52

Cannabinoids THC Therapy Patients 52

The Cannigma

DECEMBER 12, 2022

The results are so compelling that the FDA has categorized magic mushrooms as a “breakthrough therapy” for depression, and is committed to fast tracking its approval. History: MDMA was first synthesized in 1912, but it didn’t become popular until 1970, when therapists began to utilize it to enhance openness in therapy sessions.

History 141

History Microdosing Research and Development Clinical Trials 141

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., signaling, a key driver of chronic inflammation. Patent 11,219,620 B2, titled “Method of Treating Sarcopenia.” Unlike other anti-TNF-?

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Treatment 40

Green Relief

MAY 13, 2018

government-sponsored scientific research – and to extensive anecdotal accounts from medical marijuana patients – which highlight the potential of cannabinoid-based therapies for TBI. Hypothermia is typically the go-to therapy for treating newborn infants after a stroke. Complementary Therapies for TBI. Ancient therapies.

THC 64

THC CBD Cannabinoids Research and Development 64

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed SB 13 , permitting physicians to recommend cannabis therapy for any condition for which the physician “could prescribe an opioid.” Specifically, it expands the pool of patients eligible for cannabis therapy to include those with chronic pain, menstrual cramps, and epilepsy.

Legislation 45

Legislation Patients Access Banking 45

Cannabis Law Report

MAY 28, 2019

Veterans suffer widespread health problems including chronic pain, traumatic brain injuries, and post-traumatic stress disorder at a rate higher than the general population. Many patients with PTSD report having flashbacks or intrusive thoughts which result in involuntarily re-living past traumatic events.

Access 49

Access Marijuana Research and Development Programs 49